-
1
-
-
1242270459
-
Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates
-
Streit JM, Fritsche TR, Sader HS, Jones RN Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis. 2004 ; 48: 137-143.
-
(2004)
Diagn Microbiol Infect Dis
, vol.48
, pp. 137-143
-
-
Streit, J.M.1
Fritsche, T.R.2
Sader, H.S.3
Jones, R.N.4
-
2
-
-
12944275538
-
Antistaphylococcal activity of dalbavancin, an experimental glycopeptide
-
Lin G., Credito K., Ednie LM, Appelbaum PC Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother. 2005 ; 49: 770-772.
-
(2005)
Antimicrob Agents Chemother
, vol.49
, pp. 770-772
-
-
Lin, G.1
Credito, K.2
Ednie, L.M.3
Appelbaum, P.C.4
-
3
-
-
31744435192
-
Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program
-
Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis. 2006 ; 54: 149-153.
-
(2004)
Diagn Microbiol Infect Dis
, vol.54
, pp. 149-153
-
-
Jones, R.N.1
Stilwell, M.G.2
Sader, H.S.3
Fritsche, T.R.4
Goldstein, B.P.5
-
4
-
-
30744438311
-
Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): Initial results from an international surveillance protocol
-
Jones RN, Fritsche TR, Sader HS, Goldstein BP Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother. 2005 ; 17: 593-600.
-
(2005)
J Chemother.
, vol.17
, pp. 593-600
-
-
Jones, R.N.1
Fritsche, T.R.2
Sader, H.S.3
Goldstein, B.P.4
-
5
-
-
1442349121
-
Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers
-
Leighton A., Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004 ; 48: 940-945.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 940-945
-
-
Leighton, A.1
Ab, G.2
Dorr, M.B.3
-
6
-
-
27244442417
-
Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide
-
Buckwalter M., Dowell JA Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005 ; 45: 1279-1287. Addendum
-
(2005)
J Clin Pharmacol.
, vol.45
, pp. 1279-1287
-
-
Buckwalter, M.1
Dowell, J.A.2
-
7
-
-
34247130377
-
Bactericidal activity and resistance development profiling of dalbavancin
-
Goldstein BP, Draghi DC, Sheehan DJ, Hogan P., Sahm DF Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother. 2007 ; 51: 1150-1154.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 1150-1154
-
-
Goldstein, B.P.1
Draghi, D.C.2
Sheehan, D.J.3
Hogan, P.4
Sahm, D.F.5
-
8
-
-
34248331649
-
In vivo pharmacodynamic activity of the glycopeptide antibiotic dalbavancin
-
Andes DR, Craig WA In vivo pharmacodynamic activity of the glycopeptide antibiotic dalbavancin. Antimicrob Agents Chemother. 2007 ; 51: 1633-1642.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 1633-1642
-
-
Andes, D.R.1
Craig, W.A.2
-
9
-
-
0242468561
-
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections
-
Seltzer E., Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003 ; 37: 1298-1303.
-
(2003)
Clin Infect Dis
, vol.37
, pp. 1298-1303
-
-
Seltzer, E.1
Dorr, M.B.2
Goldstein, B.P.3
-
10
-
-
27644549908
-
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
-
Jauregui LE, Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005 ; 41: 1407-1415.
-
(2005)
Clin Infect Dis
, vol.41
, pp. 1407-1415
-
-
Le, J.1
Babazadeh, S.2
Seltzer, E.3
-
13
-
-
0020438086
-
Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations
-
Rothschafer JC, Crossley K., Zaske DE, Mead K., Sawchuk RJ, Solem LD Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother. 1982 ; 22: 391-394.
-
(1982)
Antimicrob Agents Chemother
, vol.22
, pp. 391-394
-
-
Rothschafer, J.C.1
Crossley, K.2
De, Z.3
Mead, K.4
Sawchuk, R.J.5
Solem, L.D.6
-
15
-
-
7444254040
-
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory infections
-
Moise-Broder PA, Forrest A., Birmingham MC, Schentag JJ Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory infections. Clin Pharmacokinet. 2004 ; 43: 925-942.
-
(2004)
Clin Pharmacokinet
, vol.43
, pp. 925-942
-
-
Moise-Broder, P.A.1
Forrest, A.2
Birmingham, M.C.3
Schentag, J.J.4
-
16
-
-
0028831358
-
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: Focus on antibacterial agents
-
Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet. 1995 ; 28: 143-160.
-
(1995)
Clin Pharmacokinet
, vol.28
, pp. 143-160
-
-
Hyatt, J.M.1
McKinnon, P.S.2
Zimmer, G.S.3
Schentag, J.J.4
|